Cost-effectiveness of perioperative mupirocin nasal ointment in cardiothoracic surgery.

OBJECTIVE To assess the cost-effectiveness of perioperative intranasal application of mupirocin calcium ointment in cardiothoracic surgery. DESIGN Cost-effectiveness analysis based on results of an intervention study with historical controls. SETTING University Hospital Rotterdam, a tertiary referral center for cardiac and pulmonary surgery. PATIENTS Consecutive patients undergoing cardiothoracic surgery between August 1, 1989, and February 1, 1991 (control group, n = 928), and between March 1, 1991, and August 1, 1992 (intervention group, n = 868). INTERVENTION Perioperative nasal application of mupirocin calcium ointment started on the day before surgery, continued for 5 days, twice daily. RESULTS Postoperative costs were increased significantly in patients with a surgical-site infection (SSI), compared with uninfected patients (P < .001). Mean SSI-attributable costs were estimated at $16,878 (95% confidence interval, $15,575-$18,181). The incidence of SSIs was 7.3% in the control group and 2.8% in the intervention group, mupirocin effectiveness being 62%. The costs of mupirocin were $11 per patient. Thus, the savings per SSI prevented were $16,633. To validate this comparative estimate of SSI-attributable costs, a noncomparative analysis of the postoperative length of stay (POLS) was performed, according to the Appropriateness Evaluation Protocol. Approximately 50% of the comparative SSI-attributable POLS were judged SSI-attributable in the noncomparative analysis. Sensitivity analyses, testing for the robustness of our conclusions, indicated that the presented model is rather insensitive to variations in the incidence of SSIs and for the effectiveness and costs of mupirocin. SSI-attributable costs were shown to be the only variable with substantial effect on the cost-effectiveness ratio. Perioperative mupirocin would result in net costs instead of savings only if SSI-attributable costs were less than $245. CONCLUSIONS SSIs in patients undergoing cardiothoracic surgery are associated with a substantial increase in postoperative costs. Provided that perioperative mupirocin reduces the SSI rate, this measure will be highly cost-effective in most centers providing cardiothoracic surgical services.

[1]  H. Verbrugh,et al.  Reduction of Surgical-Site Infections in Cardiothoracic Surgery by Elimination of Nasal Carriage of Staphylococcus aureus , 1996, Infection Control &#x0026; Hospital Epidemiology.

[2]  H. Verbrugh,et al.  Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. , 1995, The Journal of infectious diseases.

[3]  J. Kluytmans,et al.  Surveillance of postoperative infections in thoracic surgery. , 1994, The Journal of hospital infection.

[4]  B. Doebbeling,et al.  Elimination of Staphylococcus aureus Nasal Carriage in Health Care Workers: Analysis of Six Clinical Trials with Calcium Mupirocin Ointment , 1993 .

[5]  M. Schumacher,et al.  Added Hospital Stay Due to Wound Infections Following Cardiac Surgery , 1992, The Thoracic and cardiovascular surgeon.

[6]  R. Ludke,et al.  Methods for estimating days of hospitalization due to nosocomial infections. , 1992, Medical care.

[7]  L. Nicolle,et al.  Efficacy of mupirocin nasal ointment in eradicating Staphylococcus aureus nasal carriage in chronic haemodialysis patients. , 1991, The Journal of hospital infection.

[8]  B. Doebbeling,et al.  Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. , 1991, Annals of internal medicine.

[9]  B. Doebbeling,et al.  Cardiovascular surgery prophylaxis. A randomized, controlled comparison of cefazolin and cefuroxime. , 1990, The Journal of thoracic and cardiovascular surgery.

[10]  R W Stewart,et al.  J. Maxwell Chamberlain memorial paper. Sternal wound complications after isolated coronary artery bypass grafting: early and late mortality, morbidity, and cost of care. , 1990, The Annals of thoracic surgery.

[11]  J. Boyce,et al.  Hospital reimbursement patterns among patients with surgical wound infections following open heart surgery. , 1990, Infection control and hospital epidemiology.

[12]  F. Daschner.  Cost-effectiveness in hospital infection control--lessons for the 1990s. , 1989, The Journal of hospital infection.

[13]  B. Yangco,et al.  CDC definitions for nosocomial infections. , 1989, American journal of infection control.

[14]  D. Wakefield,et al.  Cost of nosocomial infection: relative contributions of laboratory, antibiotic, and per diem costs in serious Staphylococcus aureus infections. , 1988, American journal of infection control.

[15]  J M Hughes,et al.  CDC definitions for nosocomial infections, 1988. , 1988, American journal of infection control.

[16]  C. Bartzokas,et al.  Measuring the saving attributable to an antibiotic prescribing policy. , 1988, The Journal of hospital infection.

[17]  D. Kernodle,et al.  Efficacy of cefazolin, cefamandole, and gentamicin as prophylactic agents in cardiac surgery. Results of a prospective, randomized, double-blind trial in 1030 patients. , 1987, Annals of surgery.

[18]  D. Wakefield,et al.  Use of the Appropriateness Evaluation Protocol for Estimating the Incremental Costs Associated With Nosocomial Infections , 1987, Medical care.

[19]  R. M. Nelson,et al.  The economic implications of infection in cardiac surgery. , 1986, The Annals of thoracic surgery.

[20]  S. Rishpon,et al.  Reliability of a method of determining the necessity for hospitalization days in Israel. , 1986, Medical care.

[21]  P. Gertman,et al.  A comparative analysis of appropriateness of hospital use. , 1984, Health affairs.

[22]  J. Mcgowan,et al.  Methodologic issues in hospital epidemiology. III. Investigating the modifying effects of time and severity of underlying illness on estimates of cost of nosocomial infection. , 1984, Reviews of infectious diseases.

[23]  E. Rubinstein,et al.  Estimating the effects of nosocomial infections on the length of hospitalization. , 1982, The Journal of infectious diseases.

[24]  M. Modan,et al.  The effects of nosocomial infections on the length and costs of hospital stay. , 1982, The Journal of antimicrobial chemotherapy.

[25]  S. Finkler.  The distinction between cost and charges. , 1982, Annals of internal medicine.

[26]  P. Gertman,et al.  The Appropriateness Evaluation Protocol: A Technique for Assessing Unnecessary Days of Hospital Care , 1981, Medical care.

[27]  J. Mcgowan.  Cost and benefit in control of nosocomial infection: methods for analysis. , 1981, Reviews of Infectious Diseases.

[28]  R. Haley,et al.  Extra charges and prolongation of stay attributable to nosocomial infections: a prospective interhospital comparison. , 1981, The American journal of medicine.

[29]  R. Haley,et al.  Estimating the extra charges and prolongation of hospitalization due to nosocomial infections: a comparison of methods. , 1980, The Journal of infectious diseases.

[30]  B. Rosner,et al.  Adverse effects of nosocomial infection. , 1979, The Journal of infectious diseases.

[31]  R. Wenzel,et al.  Postoperative Wound Infection: A Controlled Study of the Increased Duration of Hospital Stay and Direct Cost of Hospitalization , 1977, Annals of surgery.

[32]  E. Mortimer,et al.  Importance of the carrier state as a source of Staphylococcus aureus in wound sepsis , 1969, Journal of Hygiene.

[33]  J. Griffiths,et al.  Nasal Staphylococci and Sepsis in Hospital Patients , 1959, British medical journal.

[34]  H. J. Weinstein.  The relation between the nasal-staphylococcal-carrier state and the incidence of postoperative complications. , 1959, The New England journal of medicine.

[35]  S. Clarke.  Sepsis in surgical wounds with particular reference to staphylococcus aureus , 1957, British Journal of Surgery.